Answers are grounded in this paper and cite their sources.
Antisense technologies represent a promising approach in the development of therapeutic strategies for a wide range of diseases. Advances in the understanding of disease pathogenesis and molecular mechanisms underlying gastric mucosal injury, as well as the associated signaling pathways, have enabled the identification of multiple targets for phosphorothioate antisense oligonucleotides (ASOs). In this study, we evaluated cyclooxygenase-2 (COX-2) gene expression, histological and morphological changes in the gastric tissue of Wistar rats, as well as hematological parameters and systemic physiological indicators. Phosphorothioate ASOs exhibit high sequence specificity, binding to target mRNA and inducing its degradation, thereby reducing the expression of the corresponding protein. For the first time, we report an analysis of the effects of the phosphorothioate antisense oligonucleotide Regenera-11 and its modified variants (Regenera-5′ and Regenera-3′) in a prednisolone-induced gastric mucosal injury model in Wistar rats. Suppression of COX-2 expression was associated with enhanced mucosal repair and a reduction in the severity of histological damage. These findings suggest that Regenera-11 may represent a promising candidate for further preclinical investigation and the development of targeted therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Yurchenko et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: